Clinical Pharmacy Department, El-Sheikh Zayed Specialized Hospital, Giza, Egypt.
Cardiology Department, Faculty of Medicine, Beni-suef University, Beni-suef, Egypt.
Br J Clin Pharmacol. 2022 Aug;88(8):3730-3740. doi: 10.1111/bcp.15314. Epub 2022 Mar 29.
Anticoagulants represent a main source of medication errors (MEs) and complications that have catastrophic implications, posing an obligation on health care providers to assess anticoagulant-related MEs and factors affecting their occurrence. This study investigates the occurrence and severity of prescribing MEs in patients on anticoagulants and explores their potential predictors.
This study was a prospective cohort study in a tertiary hospital on 116 patients with a total of 2166 anticoagulant doses.
Forty-four percent of prescribed anticoagulant doses resulted in MEs with low molecular weight heparin (LMWH) and unfractionated heparin (UFH) causing 61% and 34%, respectively, of the total MEs. More than 50% of all MEs were incorrect doses (high and low) shared between heparin and tinzaparin. The highest severity of error was Category D followed by Category F and Category C. A Poisson regression analysis model revealed that female (incidence rate ratio [IRR] 1.32, 95% confidence interval [CI] 1.13-1.54, P < .001), bridging (IRR 1.52; 95% CI 1.10-2.09; P = .011), venous thromboembolism (VTE) prophylaxis (IRR 7.65; 95% CI 4.88-12.02; P < .001), physician non-adherence (IRR 2.71; 95% CI 2.22-3.29; P < .001), and polypharmacy (IRR 1.68; 95% CI 1.26-2.23; P = .036) were predictors of the higher incidence of MEs. Ordinal logistic regression analysis demonstrated that physician non-adherence (OR 24.67; 95% CI 5.54-207; P < .001) was the main predictor of increased error severity.
The major predictor in increasing both the incidence and severity of MEs is physician adherence to evidence-based guidelines (EBG). Strict regulations for anticoagulant prescribing through an anticoagulant stewardship program are a necessity.
抗凝剂是药物错误(ME)和并发症的主要来源,这些错误和并发症可能带来灾难性的后果,因此医疗保健提供者有责任评估抗凝相关 ME 以及影响其发生的因素。本研究调查了接受抗凝治疗的患者中 ME 的发生和严重程度,并探讨了其潜在的预测因素。
这是一项在一家三级医院进行的前瞻性队列研究,共纳入了 116 名患者,总计 2166 剂抗凝药物。
44%的处方抗凝药物剂量导致 ME,低分子肝素(LMWH)和未分级肝素(UFH)分别导致 61%和 34%的总 ME。所有 ME 中超过 50%是肝素和那屈肝素之间的错误剂量(高剂量和低剂量)。错误严重程度最高的是类别 D,其次是类别 F 和类别 C。泊松回归分析模型显示,女性(发病率比 [IRR] 1.32,95%置信区间 [CI] 1.13-1.54,P<0.001)、桥接治疗(IRR 1.52;95%CI 1.10-2.09;P=0.011)、静脉血栓栓塞(VTE)预防(IRR 7.65;95%CI 4.88-12.02;P<0.001)、医生不遵守规定(IRR 2.71;95%CI 2.22-3.29;P<0.001)和多药治疗(IRR 1.68;95%CI 1.26-2.23;P=0.036)是 ME 发生率更高的预测因素。有序逻辑回归分析表明,医生不遵守规定(OR 24.67;95%CI 5.54-207;P<0.001)是错误严重程度增加的主要预测因素。
增加 ME 发生率和严重程度的主要预测因素是医生是否遵守基于证据的指南(EBG)。通过抗凝药物管理计划对抗凝药物的处方进行严格监管是必要的。